OPKO HEALTH, INC. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 72/100
What the filing says
On August 13, 2026, OPKO Health amended its July 2024 Note Purchase Agreement to issue $125M in additional senior secured notes (Second Closing Date Notes) to existing and new purchasers including HCR Potomac Fund II LP, HCR Stafford Fund II LP, HCRX Investments Holdco LP, and HRBR 2025-2 LLC. Total debt capacity increased from $250M (Initial Closing) to $375M. The amended agreement maintains identical terms for new notes, extends collateral pledges over royalty interests from Pfizer and Lilly license agreements, and preserves agent HCR Injection SPV LLC's first-priority security interest. Conditions precedent include regulatory compliance and post-closing Irish and Israeli law security filings.
Why this rating
Material capital raise ($125M ≈ 23% of $539.5M market cap) expands financial capacity but increases leverage. Non-dilutive structure and royalty-backed repayment limit downside risk. Significance reflects meaningful fraction of company size relative to equity capitalization; direction neutral as refinancing with existing investors suggests acceptable terms.
Price action (we called it neutral)
before filing · preread $1.65 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.